Endometrial Cancer Clinical Trials 2024

What are the top hospitals conducting endometrial cancer research?

Endometrial cancer, a type of cancer that affects the lining of the uterus, has seen significant advancements in research and treatment thanks to the efforts of top hospitals across the United States. New york's Memorial Sloan Kettering Cancer Center leads the way with an impressive 13 ongoing clinical trials dedicated to endometrial cancer. Over the years, they have conducted a total of 46 trials since their first recorded study in 2003. In Houston, M D Anderson Cancer Center is making strides as well, currently conducting 11 active endometrial cancer trials and having completed 37 studies thus far since initiating their initial trial in 2002.

Further contributing to this vital research is Massachusetts General Hospital in Boston with eight ongoing endometrial cancer trials and a history of seventeen past investigations dating back to their first recorded trial on this disease in 2005. Northwestern University in Chicago also plays a key role by conducting eight active clinical trials for endometrial cancer while having accomplished twenty-two previous studies since embarking on their inaugural trial in 2003.

Meanwhile, located at Washington University School of Medicine in St. Louis, researchers are working diligently on seven current endometrial cancer trials and have successfully completed thirty-six investigations throughout nearly three decades; theirs began all the way back when they recorded their very first trial concerning this condition backin1992.

These esteemed hospitals serve as beacons of hope for those affected by endometrial cancer - offering state-of-the-art care through cutting-edge clinical trials. By pushing boundaries and exploring new avenues for treatment options, these medical institutions are bringing us closer to breakthroughs that will improve outcomes for patients battling this complex disease nationwide

Which are the best cities for endometrial cancer clinical trials?

When it comes to endometrial cancer clinical trials, a few cities stand out as leading the way in research and development. Houston, Texas takes the lead with 51 active trials investigating treatments like Levonorgestrel-Releasing Intrauterine System, Metformin, and Lymph Node Mapping. New york, New York follows closely behind with 46 ongoing studies focused on innovative approaches such as LY3537982, Pembrolizumab, and Copanlisib. Boston, Massachusetts also plays a significant role with 33 active trials exploring options like Abemaciclib and Avelumab. These cities are at the forefront of endometrial cancer research, offering patients access to cutting-edge clinical trials that hold promise for improved treatments and outcomes.

Which are the top treatments for endometrial cancer being explored in clinical trials?

Endometrial cancer research is rapidly progressing with exciting developments in clinical trials. Leading the pack is pembrolizumab, a groundbreaking treatment currently being explored in eight active trials for endometrial cancer. Since its introduction in 2015, it has been involved in a total of 39 all-time clinical trials dedicated to combating this form of cancer. Close behind are niraparib and abemaciclib, both showing promise with three ongoing trials each and accumulating eight and six all-time endometrial cancer trials respectively since their first listings in 2017 and 2018. Also making strides is pembrolizumab, featuring prominently with two active trials and four all-time endometrial cancer studies since its debut alongside other promising treatments on the horizon.

What are the most recent clinical trials for endometrial cancer?

Exciting advancements in the field of endometrial cancer research offer hope for improved treatment options. Recent clinical trials have explored various approaches to combat this disease. NPX267, a Phase 1 trial, has shown promise as a potential treatment for endometrial cancer. Additionally, PRO1184 is being investigated in both Phase 1 and Phase 2 trials, with the aim of enhancing outcomes for patients with this condition. Another study focused on combining BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel to target endometrial cancer cells effectively. Furthermore, SGN-ALPV and copanlisib are also undergoing investigation as potential therapies in separate clinical trials for endometrial cancer management. These ongoing studies provide renewed optimism and hold great potential for future treatment strategies against endometrial cancer.

What endometrial cancer clinical trials were recently completed?

In the realm of endometrial cancer, several clinical trials have recently reached completion, bringing hope for improved treatment options. Among them, a trial sponsored by Byondis B.V., exploring the potential of SYD985, concluded in May 2020. Additionally, the Medical College of Wisconsin completed a trial studying Rucaparib in July 2019. Notably, Xencor Inc.'s XmAb®22841 trial wrapped up in May 2019 as well. These advancements signify significant progress and emphasize ongoing efforts to combat endometrial cancer and enhance patient outcomes.